+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Forecast 2023-2030

  • PDF Icon

    Report

  • 184 Pages
  • November 2023
  • Region: Global
  • 360iResearch™
  • ID: 5592101
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer/Tumor Profiling Market size was estimated at USD 9.13 billion in 2022, USD 10.79 billion in 2023, and is expected to grow at a CAGR of 18.67% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

Regional Insights

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, re?ecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer/Tumor Profiling Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Immunoassays
    • In-Situ Hybridization
    • Mass Spectrometry
    • Microarrays
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Biomarker Type
    • Genomic Biomarker
    • Protein Biomarker
  • Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Melanoma Cancer
    • Prostate Cancer
  • Application
    • Biomarker Discovery
    • Clinical Application
    • Diagnostics
    • Personalized Medicine
    • Prognostics
    • Research
    • Screening
    • Treatment & Monitoring
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cancer/Tumor Profiling Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer/Tumor Profiling Market?
  3. What are the technology trends and regulatory frameworks in the Cancer/Tumor Profiling Market?
  4. What is the market share of the leading vendors in the Cancer/Tumor Profiling Market?
  5. Which modes and strategic moves are suitable for entering the Cancer/Tumor Profiling Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Frequently Asked Questions about the Global Cancer/Tumor Profiling Market

What is the estimated value of the Global Cancer/Tumor Profiling Market?

The Global Cancer/Tumor Profiling Market was estimated to be valued at $10.79 Billion in 2023.

What is the growth rate of the Global Cancer/Tumor Profiling Market?

The growth rate of the Global Cancer/Tumor Profiling Market is 18.6%, with an estimated value of $35.94 Billion by 2030.

What is the forecasted size of the Global Cancer/Tumor Profiling Market?

The Global Cancer/Tumor Profiling Market is estimated to be worth $35.94 Billion by 2030.

Who are the key companies in the Global Cancer/Tumor Profiling Market?

Key companies in the Global Cancer/Tumor Profiling Market include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann, La Roche Ltd. and GENINUS Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer/Tumor Profiling Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
5.1.1.3. Surging preference for personalized medicines for cancer treatment
5.1.2. Restraints
5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
5.1.3. Opportunities
5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
5.1.4. Challenges
5.1.4.1. Low biomarker discovery-to-approval ratio
5.2. Market Segmentation Analysis
5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
5.3. Market Trend Analysis
5.3.1. Government initiatives for cancer diagnostics with rapid advancements in cancer/tumor profiling solutions
5.3.2. Rising cancer prevalence with evolving cancer research initiatives enhancing the need for novel cancer/tumor profiling in the APAC region
5.3.3. Increasing adoption of precision medicines and genetic profiling solutions to overcome the cancer burden across EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Cancer/Tumor Profiling Market, by Technology
6.1. Introduction
6.2. Immunoassays
6.3. In-Situ Hybridization
6.4. Mass Spectrometry
6.5. Microarrays
6.6. Next-Generation Sequencing
6.7. Polymerase Chain Reaction
7. Cancer/Tumor Profiling Market, by Biomarker Type
7.1. Introduction
7.2. Genomic Biomarker
7.3. Protein Biomarker
8. Cancer/Tumor Profiling Market, by Cancer Type
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Melanoma Cancer
8.6. Prostate Cancer
9. Cancer/Tumor Profiling Market, by Application
9.1. Introduction
9.2. Biomarker Discovery
9.3. Clinical Application
9.4. Diagnostics
9.5. Personalized Medicine
9.6. Prognostics
9.7. Research
9.8. Screening
9.9. Treatment & Monitoring
10. Americas Cancer/Tumor Profiling Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cancer/Tumor Profiling Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
13.3.1.2. Prenetics Acquires ACT Genomics
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
13.3.2.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
13.3.2.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
13.3.3. New Product Launch & Enhancement
13.3.3.1. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
13.3.3.2. ??Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
13.3.4. Investment & Funding
13.3.4.1. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
13.3.4.2. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
13.3.5.2. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. 4basecare Onco Solutions Private Limited
14.1.2. ACT Genomics Co., Ltd. by Prenetics Global Limited
14.1.3. Agendia, Inc.
14.1.4. Agilent Technologies, Inc.
14.1.5. BostonGene Corporation
14.1.6. Caris Life Sciences
14.1.7. Exact Sciences Corporation
14.1.8. F. Hoffmann-La Roche Ltd.
14.1.9. GENINUS Inc.
14.1.10. Genomic Life
14.1.11. GenScript Biotech Corporation
14.1.12. Guardant Health, Inc.
14.1.13. Hologic, Inc.
14.1.14. HTG Molecular Diagnostics, Inc.
14.1.15. Illumina, Inc.
14.1.16. IMBdx, Inc.
14.1.17. Laboratory Corporation of America Holdings
14.1.18. Lucence Health, Inc.
14.1.19. Merck KGaA
14.1.20. NanoString Technologies, Inc.
14.1.21. Neogenomics, Inc.
14.1.22. Nonacus Limited
14.1.23. OncoDNA S.A.
14.1.24. Oncompass Medicine Hungary Kft.
14.1.25. Paragon Genomics, Inc.
14.1.26. Personalis, Inc.
14.1.27. Perthera, Inc.
14.1.28. Predictive Oncology Inc.
14.1.29. Strand Life Sciences
14.1.30. Sysmex Corporation
14.1.31. Takara Bio Inc.
14.1.32. Tempus Labs Inc.
14.1.33. Thermo Fisher Scientific Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. CANCER/TUMOR PROFILING MARKET RESEARCH PROCESS
FIGURE 2. CANCER/TUMOR PROFILING MARKET SIZE, 2022 VS 2030
FIGURE 3. CANCER/TUMOR PROFILING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. CANCER/TUMOR PROFILING MARKET DYNAMICS
FIGURE 7. CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 8. CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2022 VS 2030 (%)
FIGURE 10. CANCER/TUMOR PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
FIGURE 12. CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 14. CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER/TUMOR PROFILING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 24. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2022

Companies Mentioned

  • 4basecare Onco Solutions Private Limited
  • ACT Genomics Co., Ltd. by Prenetics Global Limited
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • BostonGene Corporation
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GENINUS Inc.
  • Genomic Life
  • GenScript Biotech Corporation
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • IMBdx, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health, Inc.
  • Merck KGaA
  • NanoString Technologies, Inc.
  • Neogenomics, Inc.
  • Nonacus Limited
  • OncoDNA S.A.
  • Oncompass Medicine Hungary Kft.
  • Paragon Genomics, Inc.
  • Personalis, Inc.
  • Perthera, Inc.
  • Predictive Oncology Inc.
  • Strand Life Sciences
  • Sysmex Corporation
  • Takara Bio Inc.
  • Tempus Labs Inc.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...